A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117) Meeting Abstract
| Authors: | Fuchs, C. S.; Tabernero, J.; Al-Batran, S. E.; Chau, I.; Ilson, D. H.; Van Cutsem, E.; Ferry, D.; Emig, M.; Melemed, A. S.; Vanvoorden, V.; Hsu, Y. Z.; Xu, Y. H.; Sashegyi, A.; Das, M.; Shah, M. A. |
| Abstract Title: | A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117) |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904739 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps4131 |
| Notes: | Meeting Abstract: TPS4131 -- Source: Wos |
